Prospective study of Transcatheter arterial chemoembolization (Tace) with ginsenoside rg3 versus Tace alone for the Treatment of Patients with advanced hepatocellular carcinoma

Radiology

Volumn 280, Issue 2, 2016, Pages 630-639

  Zhou, Bo ^a   Yan, Zhiping ^a   Liu, Rong ^a   Shi, Peng ^a,b   Qian, Sheng ^a   Qu, Xudong ^a   Zhu, Liang ^a   Zhang, Wei ^a   Wang, Jianhua ^a  

^a FUDAN UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; FLUOROURACIL; GELATIN SPONGE; GINSENOSIDE RG 3; IODINATED POPPYSEED OIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; GINSENOSIDE;

ADULT; ADVANCED CANCER; ALBUMINURIA; ANEMIA; ANGIOGRAPHIC CATHETER; ANGIOGRAPHY; ANOREXIA; ARTICLE; ASCITES; CANCER GROWTH; CANCER REGISTRY; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPUTED TOMOGRAPHY SCANNER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LEUKOPENIA; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MICROCATHETER; NAUSEA; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; VOMITING; CARCINOMA, HEPATOCELLULAR; COMPARATIVE STUDY; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; PROSPECTIVE STUDY; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; FEMALE; GINSENOSIDES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84979943847     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016150719     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90.
2. Mazzaferro V, Lencioni R, Majno P. Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. Semin Liver Dis 2014;34(4):415-426.
3. Morise Z, Kawabe N, Tomishige H, et al. Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gas-troenterol 2014;20(39):14381-14392.
4. Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005;100(9):1995-2004.
5. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30(1):6-25.
6. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319):1734-1739.
7. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellu-lar carcinoma: chemoembolization improves survival. Hepatology 2003;37(2):429-442.
8. Takayasu K, Arii S, Ikai I, et al. Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. AJR Am J Roent-genol 2010;194(3):830-837.
9. Luo J, Guo RP, Lai EC, et al. Transarterial chemoembolization for unresectable hepa-tocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study. Ann Surg Oncol 2011;18(2):413-420.
10. Chung GE, Lee JH, Kim HY, et al. Trans-arterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011;258(2):627-634.
11. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther 2008;8(11):1743-1749.
12. Sergio A, Cristofori C, Cardin R, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 2008;103(4):914-921.
13. Mathonnet M, Descottes B, Valleix D, Labrousse F, Truffnet V, Denizot Y. Quantitative analysis using ELISA of vascular en-dothelial growth factor and basic fbroblast growth factor in human colorectal cancer, liver metastasis of colorectal cancer and he-patocellular carcinoma. World J Gastroen-terol 2006;12(23):3782-3783.
14. Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarte-rial chemoembolization versus sorafenib. Radiology 2012;263(2):590-599.
15. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359(4):378-390.
16. Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with transarterial chemoem-bolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study. J Dig Dis 2013;14(4):181-190.
17. Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with tran-sarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology 2013; 269(2):603-611.
18. Kim J W, Jung SY, Kwon YH, et al. Ginsen-oside Rg3 inhibits endothelial progenitor cell differentiation through attenuation of VEGF-dependent Akt/eNOS signaling. Phy-tother Res 2012;26(9):1286-1293.
19. Chen QJ, Zhang MZ, Wang LX. Gensen-oside Rg3 inhibits hypoxia-induced VEGF expression in human cancer cells. Cell Physiol Biochem 2010;26(6):849-858.
20. Wang JH, Nao JF, Zhang M, He P. 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways. Tumour Biol 2014;35(12):11985-11994.
21. Kim DG, Jung KH, Lee DG, et al. 20(S)-ginsenoside Rg3 is a novel inhibitor of au-tophagy and sensitizes hepatocellular carcinoma to doxorubicin. Oncotarget 2014; 5(12):4438-4451.
22. Zhang C, Liu L, Yu Y, Chen B, Tang C, Li X. Antitumor effects of ginsenoside Rg3 on human hepatocellular carcinoma cells. Mol Med Rep 2012;5(5):1295-1298.
23. Lee YJ, Lee S, Ho JN, et al. Synergistic an-titumor effect of ginsenoside Rg3 and cis-platin in cisplatin-resistant bladder tumor cell line. Oncol Rep 2014;32(5):1803-1808.
24. Sun Y, Lin H, Zhu Y, et al. A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine+cisplatin) plus gensing Rg3 in the treatment of advanced non-small cell lung cancer patients [in Chinese]. Zhongguo Fei Ai Za Zhi 2006;9(3): 254-258.
25. Zhou B, Wang J, Yan Z. Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an or-thotopic transplantation hepatocellular carcinoma rat model. Onco Targets Ther 2014; 7:1945-1954.
26. Health Bureau of China. Chinese guideline for HCC. Chin Clin Oncol 2011;16(10):929-946.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
28. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13(3):176-181.
29. Peixoto RD, Renouf DJ, Gill S, Cheung WY, Lim HJ. Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. J Gastrointest Oncol 2014;5(4):259-264.
30. Kelley RK. Brivanib and FOLFOX in hepa-tocellular carcinoma: fnding the common themes among negative trials. J Clin Oncol 2013;31(28):3483-3486.